Very Early PET-response Adapted Targeted Therapy for Advanced Hodgkin Lymphoma: a Single -Arm Phase II Study

Summary

The main objective of this trial is to assess whether treatment adaptation based on a very early FDG-PET/CT results in improved efficacy while minimizing treatment toxicity in advanced stage Hodgkin Lymphoma (HL) patients treated with brentuximab vedotin (BV)-containing regimens.

Timeline

Start

2019-08-01

Primary completion

2023-08-28

Completion

2026-11-16

Publications

• Hutchings M, Diepstra A, Sureda Balari A, Carvalho S, Vranovsky A, Noordzij W, Loft A, Arens A, Teesink S, Visser L, Stevens W, Aleman BMP, Woei-A-Jin FJSH, Viguria M, Saevels K, Te Boome L, Tonino S, Meijnders P, Domingo Domenech E, Hasselbalch Riley C, Musekera L, Nuyens S, Mallien C, Sents W, Buhrer E, Fortpied C, Plattel WJ. Very early [18F]FDG-PET-guided targeted therapy in untreated advanced-stage classic Hodgkin lymphoma (EORTC-1537-COBRA): primary results of a single-arm, multicentre, phase 2 trial. Lancet Haematol. 2026 May;13(5):e274-e283. doi: 10.1016/S2352-3026(26)00068-2.
• Kreuzberger N, Goldkuhle M, von Tresckow B, Kobe C, Sickinger MT, Monsef I, Skoetz N. Positron emission tomography-adapted therapy for first-line treatment in adults with Hodgkin lymphoma. Cochrane Database Syst Rev. 2025 Mar 26;3(3):CD010533. doi: 10.1002/14651858.CD010533.pub3.

Drugs

Indications